首页> 外文期刊>Journal of Intercultural Ethnopharmacology >The availability and validity of safety information of Over the Counter herbal products for use in diabetes in Sri Lanka: a cross sectional study.
【24h】

The availability and validity of safety information of Over the Counter herbal products for use in diabetes in Sri Lanka: a cross sectional study.

机译:斯里兰卡糖尿病用非处方草药产品安全性信息的可用性和有效性:一项横断面研究。

获取原文
       

摘要

The availability and validity of safety information of Over the Counter herbal products for use in diabetes in Sri Lanka: a cross sectional study. Background: There is an increase of over-the-counter (OTC) herbal products for use in diabetes mellitus.. The aim of this study is to evaluate the safety information provided with OTC herbal remedies intended for diabetic patients in Sri Lanka and to assess the completeness of the information provided. Methods: Inclusion criteria consisted of OTC herbal remedies meant for use in diabetes. They were bought from local Sri Lankan super markets and non-Ayurvedic pharmacies and product information regarding the risk of hypoglycaemia, precautions for use, adverse events, dose and interactions were assessed using a scoring system. The accuracy of the information was then compared against published data. Results: Eleven products fulfilled the inclusion criteria. Five products contained a single constituent and 5 contained more than one. None had complete and accurate safety information according to our criteria. None specifically warned against the risk of hypoglycaemia. Nine out of eleven products (81.8%)carried Conclusions: Key safety information was absent in most products. Regulation of sale, provision of key safety information and adverse event reporting should be a priority.
机译:斯里兰卡糖尿病用非处方草药产品安全性信息的可用性和有效性:一项横断面研究。背景:用于糖尿病的非处方(OTC)草药产品有所增加。本研究的目的是评估针对斯里兰卡糖尿病患者的OTC草药提供的安全性信息,并评估提供的信息的完整性。方法:纳入标准由旨在用于糖尿病的非处方药组成。它们是从斯里兰卡当地的超市和非阿育吠陀药房购买的,并使用评分系统评估了有关低血糖风险,使用注意事项,不良事件,剂量和相互作用的产品信息。然后将信息的准确性与发布的数据进行比较。结果:11种产品符合纳入标准。五种产品包含一种成分,而五种包含一种以上成分。根据我们的标准,没有人拥有完整,准确的安全信息。没有人特别警告不要发生低血糖的风险。 11种产品中有9种(81.8%)带有结论:大多数产品中都没有关键的安全信息。销售法规,关键安全信息的提供和不良事件的报告应成为优先事项。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号